Jones RJ, Lee KSK, Beschomer WE. Veno-occlusive disease of the liver following bone marrow transplantation[J]. Transplantation, 1987, 44(2): 778-783.
[2]
Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver[J]. J Clin Pathol, 1982, 35(10): 1086-1091.
[3]
Jacobs SS, Stork LC, Bostrom BC, Hutchinson R, Holcenberg J, Reaman GH, et al. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Childrens Oncology Group/National Cancer Institute Pilot Trial (CCG-1942)[J]. Pediatr Blood Cancer, 2007, 49(3): 250-255.
[4]
Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomized trial[J]. Lancet, 2006, 368(9544): 1339-1348.
[5]
Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia[J]. Clin Pharmacol Ther, 2006, 80(4): 375-383.
[6]
Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies[J]. Bone Marrow Transplant, 2008, 41(3): 229-237.
[7]
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial[J]. Biol Blood Marrow Transplant, 2010, 16(7): 1005-1017.
[8]
Narita M, Oussoultzoglou E, Chenard MP, Rosso E, Casnedi S, Pessaux P, et al. Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization[J]. Surg Today, 2011, 41(1): 7-17.
[9]
Sakaguchi H, Watanabe N, Muramatsu H, Doisaki S, Yoshida N, Matsumoto K, et al. Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy[J]. Pediatr Blood Cancer, 2010, 55(6): 1118-1125.
